Dizal Pharmaceutical's Hong Kong IPO Prospectus Lapses

Stock News

昨天

The Hong Kong IPO prospectus submitted by Dizal Pharmaceutical Co.,Ltd. (688192.SH) on January 23, 2026, has lapsed as of July 23, 2026, after being active for six months. Goldman Sachs and Huatai International were the joint sponsors at the time of filing.

According to the prospectus, Dizal Pharmaceutical is a commercial-stage biopharmaceutical company focused on oncology and hematological diseases. Its marketed product, Sunvozertinib®, is the only small-molecule epidermal growth factor receptor tyrosine kinase inhibitor globally approved for treating non-small cell lung cancer with EGFR exon 20 insertion mutations.

For the fiscal year 2023, the fiscal year 2024, and the nine months ended September 30, 2025, the company reported revenues of approximately RMB 91.3 million, RMB 360 million, and RMB 586 million, respectively.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1159047255"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1159047255\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1159047255?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-23 10:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159047255","market":"us","top_or_hot":-1,"title":"Dizal Pharmaceutical's Hong Kong IPO Prospectus Lapses","media":"Stock News","content":"<p>The Hong Kong IPO prospectus submitted by <b>Dizal Pharmaceutical Co.,Ltd.</b> (688192.SH) on January 23, 2026, has lapsed as of July 23, 2026, after being active for six months. Goldman Sachs and Huatai International were the joint sponsors at the time of filing.<br><br>According to the prospectus, Dizal Pharmaceutical is a commercial-stage biopharmaceutical company focused on oncology and hematological diseases. Its marketed product, Sunvozertinib®, is the only small-molecule epidermal growth factor receptor tyrosine kinase inhibitor globally approved for treating non-small cell lung cancer with EGFR exon 20 insertion mutations.<br><br>For the fiscal year 2023, the fiscal year 2024, and the nine months ended September 30, 2025, the company reported revenues of approximately RMB 91.3 million, RMB 360 million, and RMB 586 million, respectively.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dizal Pharmaceutical's Hong Kong IPO Prospectus Lapses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDizal Pharmaceutical's Hong Kong IPO Prospectus Lapses\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-07-23 10:53</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>The Hong Kong IPO prospectus submitted by <b>Dizal Pharmaceutical Co.,Ltd.</b> (688192.SH) on January 23, 2026, has lapsed as of July 23, 2026, after being active for six months. Goldman Sachs and Huatai International were the joint sponsors at the time of filing.<br><br>According to the prospectus, Dizal Pharmaceutical is a commercial-stage biopharmaceutical company focused on oncology and hematological diseases. Its marketed product, Sunvozertinib®, is the only small-molecule epidermal growth factor receptor tyrosine kinase inhibitor globally approved for treating non-small cell lung cancer with EGFR exon 20 insertion mutations.<br><br>For the fiscal year 2023, the fiscal year 2024, and the nine months ended September 30, 2025, the company reported revenues of approximately RMB 91.3 million, RMB 360 million, and RMB 586 million, respectively.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"REDS","symbol_name":"RPM Republican Senate ETF","start_time":0,"source_url":"","article_id":"1159047255","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159047255","pubTimestamp":1784775187,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"The Hong Kong IPO prospectus submitted by Dizal Pharmaceutical Co.,Ltd. (688192.SH) on January 23, 2026, has lapsed as of July 23, 2026, after being active for six months. Goldman Sachs and Huatai...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","688192":"迪哲医药-U","REDS":"RPM Republican Senate ETF","BK1515":"抗疫概念","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1161":"生物科技","FRHC":"Euronext CAC Health Care","09939":"开拓药业-B","BK1574":"生物医药B类股","BK4127":"投资银行业与经纪业","IPOS":"Renaissance International IPO ETF","BK0239":"医药制造","KCE":"SPDR KBW Capital Markets ETF","VXUS":"国际股票ETF-Vanguard","KCAI":"KraneShares China Alpha Index ETF"},"translate_title":"迪扎尔制药香港IPO招股说明书失效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"688192":1,"REDS":1,"IPOS":1,"KCAI":1,"VXUS":1,"FRHC":1,"09939":1,"KCE":1},"content_text":"The Hong Kong IPO prospectus submitted by Dizal Pharmaceutical Co.,Ltd. (688192.SH) on January 23, 2026, has lapsed as of July 23, 2026, after being active for six months. Goldman Sachs and Huatai International were the joint sponsors at the time of filing.According to the prospectus, Dizal Pharmaceutical is a commercial-stage biopharmaceutical company focused on oncology and hematological diseases. Its marketed product, Sunvozertinib®, is the only small-molecule epidermal growth factor receptor tyrosine kinase inhibitor globally approved for treating non-small cell lung cancer with EGFR exon 20 insertion mutations.For the fiscal year 2023, the fiscal year 2024, and the nine months ended September 30, 2025, the company reported revenues of approximately RMB 91.3 million, RMB 360 million, and RMB 586 million, respectively.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}